A Phase 3 interventional study of Active Comparator: Olaparib tablets and Placebo in Epithelial Ovarian Cancer, sponsored by AstraZeneca. Completed at 82 sites in 11 countries. Open to female participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2022-10-07.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies in Carcinoma, Ovarian Epithelial with a site in France — 10 open to participants now, 14 under way, 5 of them phase 3. Carcinoma, Ovarian Epithelial · France.
Among the 46 studies in Carcinoma, Ovarian Epithelial with a site in France, this one is the 23rd largest by enrollment of the 40 interventional ones that give a count, is one of 3 that started in 2017, is one of 17 in phase 3, and was the 25th registered.
798 studies on the registry are indexed under Carcinoma, Ovarian Epithelial; 102 are open to participants now.
Browse Carcinoma, Ovarian Epithelial studies →10 of the 46 studies in Carcinoma, Ovarian Epithelial with a site in France are open now. Recruiting first, the newest first:
AstraZeneca · Sites in France, United States, Argentina and 26 more countries
Ages 18+ · Women only
AstraZeneca · Sites in France, United States, Australia and 21 more countries
Ages 18+ · Women only
Daiichi Sankyo · Sites in France, United States, Australia and 23 more countries
Ages 18+ · Women only
TORL Biotherapeutics, LLC · Sites in France, United States, Australia and 9 more countries
Ages 18+ · Women only
Guardant Health, Inc. · Sites in France, United States, Germany and 2 more countries
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 75 Carcinoma, Ovarian Epithelial studies recruiting now, 50 (67%) set no upper age limit and 12 (16%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.
This study: 18 Years to 130 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 13 · Phase 3 17
First in 1996; this study’s year is marked. 3 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 220 is above the median of 45 across 585 interventional studies indexed under Carcinoma, Ovarian Epithelial.
Median enrollment 245 across the 40 interventional studies, 500 across the 5 observational. Of the 25 that completed or were terminated, 6 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 46 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
AstraZeneca has 7 studies filed under Carcinoma, Ovarian Epithelial — fewer than ten, so there is no comparison to draw.
4 of the studies in Carcinoma, Ovarian Epithelial with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03976999Institut du Cancer de Montpellier - Val d'AurelleDevelopment of a Cinical and Biological Database in Ovarian, Fallopian Tube and Peritoneal Cancers | 2027-07 |
| NCT05238922Incyte CorporationStudy of INCB123667 in Subjects With Advanced Solid Tumors | 2027-07-27 |
| NCT06690775TORL Biotherapeutics, LLCCATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer. | 2027-10 |
| NCT05544929Novartis PharmaceuticalsA Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers | 2027-10-05 |
Add all 4 to your calendar (.ics) → With an account.
Among the 46 studies in Carcinoma, Ovarian Epithelial with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The OReO study will be a Phase IIIb, randomised, double-blind, placebo-controlled, multicentre study to assess the efficacy and tolerability of Olaparib retreatment, versus matching placebo, in non-mucinous epithelial ovarian cancer (EOC) patients (including patients with primary peritoneal and/or fallopian tube cancer)
The OReO study will investigate the efficacy and safety of Olaparib maintenance re-treatment in patients with relapsed non-mucinous EOC, who have had disease progression following maintenance therapy with a Polyadenosine 5'diphosphoribose [poly (ADP ribose)] polymerisation inhibitor (PARPi) and a complete or partial radiological response to subsequent treatment with platinum-based chemotherapy or may have no evidence of disease (if optimal cytoreductive surgery was conducted prior to chemotherapy), and no evidence of a rising CA-125. Patients will be enrolled on the basis of their breast cancer susceptibility gene (BRCA1, BRCA2) status into one of two cohorts (BRCA1/2 [+ve] and BRCA1/2 [-ve]). The BRCA1/2 (+ve) and BRCA1/2 (-ve) cohorts will be randomised separately. Within each cohort, patients will be randomised by prospective allocation in a 2:1 ratio (Olaparib: matching placebo).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients must not have received bevacizumab during this course of treatment. Bevacizumab use as part of an earlier line of chemotherapy is permitted Patients must not have received any agent during this course of treatment Patients must be randomised within 8 weeks of their last dose of chemotherapy (last dose is the day of the last infusion)
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Olaparib 300mg tablets administered orally twice daily continuously.
Drug: Active Comparator: Olaparib tablets
Matching placebo 300mg tablets administered orally twice daily continuously.
Drug: Placebo
Olaparib 300mg Olaparib tablets taken orally twice daily (except where this dose and formulation was previously not tolerated) until objective radiological disease progression as per RECIST 1.1 or as long as in the Investigator's opinion they are benefiting from treatment and they do not meet any other discontinuation criteria.
Also known as: Olaparib tablets
Placebo 300mg placebo tablets taken orally twice daily (except where this dose and formulation was previously not tolerated) until objective radiological disease progression as per RECIST 1.1 or as long as in the Investigator's opinion they are benefiting from treatment and they do not meet any other discontinuation criteria.
Efficacy: Progression-free Survival (PFS)
PFS (per RECIST 1.1) was defined as the time from randomisation until the date of Investigator assessed objective radiological disease progression or death (by any cause in the absence of disease progression). Objective progression (per RECIST 1.1) is defined as at least a 20% increase in the sum of the diameters of the target lesions and an absolute increase of \>5 mm, or an overall non-target lesion assessment of progression or a new lesion. Patients who have not progressed or died at the time of analysis were censored at the time of the latest date of assessment from their last evaluable RECIST assessment.
Time frame: At randomization visit and at every 12 weeks (+/- 7 days) until objective radiological disease progression as determined by the investigator or other discontinuation criteria are met (assessed upto 3.8 years)
Efficacy: Overall Survival (OS)
OS was defined as the time from the date of randomisation until death due to any cause. Any patient not known to have died at the time of analysis was censored based on the last recorded date on which the patient was known to be alive
Time frame: From randomisation till Long-term follow-up (12-weekly beyond 30 days after last dose of study treatment) assessed upto 3.8 years
Efficacy: Time to Progression by Gynecologic Cancer Intergroup (GCIG) Criteria
Time to progression by RECIST or CA-125 or death is defined as the time from randomisation to the earlier date of RECIST progression or CA-125 progression or death by any cause. Patients without a CA-125 progression or a RECIST progression who are still alive at the time of analysis will be censored at the time of their last evaluable RECIST assessment and/or their last available CA-125 measurement, whichever is the earliest at the time of analysis. Patients that do not have any evaluable RECIST assessments or any CA-125 results post-randomisation will be censored at the date of randomisation
Time frame: At screening (Visit 1) and at every 12 weeks (±7 days), until objective disease progression, based on progressive serial elevation of serum CA-125 according to the GCIG criteria, or until discontinuation for other reasons (assessed upto 3.8 years)
Efficacy: Time to First Subsequent Treatment Commencement (TFST)
TFST was assessed as time from randomisation to first subsequent treatment commencement or death if this occurs before commencement of first subsequent treatment. Any patient not known to have had a further subsequent therapy or death was censored at the last known time to have not received subsequent therapy
Time frame: From follow-up i.e. 30 days after last dose of study medication till end of study (assessed every 12 weeks upto 3.8 years)
Efficacy: Time to Second Subsequent Treatment Commencement (TSST)
TSST was assessed as time from randomisation to second subsequent treatment commencement or death if this occurs before commencement of second subsequent treatment. Any patient not known to have had a further second subsequent therapy or death was censored at the last known time to have not received second subsequent therapy
Time frame: From follow-up i.e. 30 days after last dose of study medication till end of study (assessed every 12 weeks upto 3.8 years)
Efficacy: Time to Study Treatment Discontinuation (TDT)
TDT was assessed as time from randomisation to study treatment discontinuation or death if this occurs before discontinuation of study treatment. Any patient not known to have died at the time of analysis and not known to have discontinued study treatment was censored based on the last recorded date on which the patient was known to be alive
Time frame: From follow-up 30 days after last dose of study medication till long-term follow-up i.e. 12-weekly beyond 30 days after last dose of study treatment
Efficacy: Change From Baseline in Health-related Quality of Life (HRQoL)
Health related quality of life (HRQoL) of Olaparib maintenance retreatment compared to placebo as measured by the Functional Assessment of Cancer Therapy - Ovarian (FACT-O) Trial Outcome Index (TOI) was determined. HRQoL was analysed using the FACT-O tool by mixed model for repeated measures (MMRM) analysis of the change from baseline in TOI score. FACT-O TOI is scored from O to 100 with higher scores denoting better quality of life. The higher the score, the better the HRQoL.
Time frame: At Baseline, and from Day 1 until objective disease progression (assessed upto 2 years)
Number of Patients With Adverse Events (AEs), and Serious Adverse Events (SAEs)
All AEs/serious adverse events (SAEs) reported during the study were recorded.
Time frame: At Baseline and from Day 1 till follow-up i.e. 30 days after last dose of study medication (assessed upto 3.8 years)
Number of Patients With Adverse Event of Special Interest (AESI).
All AESIs reported during the study were recorded.
Time frame: At Baseline and from Day 1 till long-term follow-up i.e. 12-weekly beyond 30 days after last dose of study treatment (assessed upto 3.8 years)
This study was conducted at study centres in 11 countries (France, Italy, Spain, Germany, Poland, Belgium, Denmark, Israel, United Kingdom, Norway, and Canada) between 8-Jun-2017 and 15-Feb-2021.
| Milestone | Olaparib (BRCA1/2 +ve) | Placebo (BRCA1/2 +ve) | Olaparib (BRCA1/2 -ve) | Placebo (BRCA1/2 -ve) |
|---|---|---|---|---|
| Started | 74 | 38 | 72 | 36 |
| Completed | 30 | 15 | 54 | 25 |
| Not completed | 44 | 23 | 18 | 11 |
| Withdrew: Death | 37 | 22 | 12 | 8 |
| Withdrew: Lost to follow-up | 2 | 0 | 2 | 2 |
| Withdrew: Withdrawal by subject | 5 | 1 | 4 | 1 |
PFS (per RECIST 1.1) was defined as the time from randomisation until the date of Investigator assessed objective radiological disease progression or death (by any cause in the absence of disease progression). Objective progression (per RECIST 1.1) is defined as at least a 20% increase in the sum of the diameters of the target lesions and an absolute increase of \>5 mm, or an overall non-target lesion assessment of progression or a new lesion. Patients who have not progressed or died at the time of analysis were censored at the time of the latest date of assessment from their last evaluable RECIST assessment.
| Months | Olaparib (BRCA1/2 +ve) | Placebo (BRCA1/2 +ve) | Olaparib (BRCA1/2 -ve) | Placebo (BRCA1/2 -ve) |
|---|---|---|---|---|
| Efficacy: Progression-free Survival (PFS) | 4.3 (2.79 to 5.49) | 2.8 (2.73 to 4.96) | 5.3 (2.89 to 5.55) | 2.8 (2.79 to 2.89) |
OS was defined as the time from the date of randomisation until death due to any cause. Any patient not known to have died at the time of analysis was censored based on the last recorded date on which the patient was known to be alive
| Months | Olaparib (BRCA1/2 +ve) | Placebo (BRCA1/2 +ve) | Olaparib (BRCA1/2 -ve) | Placebo (BRCA1/2 -ve) |
|---|---|---|---|---|
| Efficacy: Overall Survival (OS) | 20.1 (16.39 to 25.43) | 20.9 (15.21 to 23.92) | 23.2 (15.15 to NA) | 30.2 (17.84 to NA) |
Time to progression by RECIST or CA-125 or death is defined as the time from randomisation to the earlier date of RECIST progression or CA-125 progression or death by any cause. Patients without a CA-125 progression or a RECIST progression who are still alive at the time of analysis will be censored at the time of their last evaluable RECIST assessment and/or their last available CA-125 measurement, whichever is the earliest at the time of analysis. Patients that do not have any evaluable RECIST assessments or any CA-125 results post-randomisation will be censored at the date of randomisation
| Months | Olaparib (BRCA1/2 +ve) | Placebo (BRCA1/2 +ve) | Olaparib (BRCA1/2 -ve) | Placebo (BRCA1/2 -ve) |
|---|---|---|---|---|
| Efficacy: Time to Progression by Gynecologic Cancer Intergroup (GCIG) Criteria | 2.8 (2.76 to 5.36) | 2.8 (2.73 to 3.98) | 2.9 (2.79 to 5.32) | 2.79 (2.63 to 2.79) |
TFST was assessed as time from randomisation to first subsequent treatment commencement or death if this occurs before commencement of first subsequent treatment. Any patient not known to have had a further subsequent therapy or death was censored at the last known time to have not received subsequent therapy
| Months | Olaparib (BRCA1/2 +ve) | Placebo (BRCA1/2 +ve) | Olaparib (BRCA1/2 -ve) | Placebo (BRCA1/2 -ve) |
|---|---|---|---|---|
| Efficacy: Time to First Subsequent Treatment Commencement (TFST) | 5.8 (4.67 to 9.17) | 5.1 (3.58 to 6.11) | 7.9 (5.88 to 11.07) | 4.3 (3.68 to 6.41) |
TSST was assessed as time from randomisation to second subsequent treatment commencement or death if this occurs before commencement of second subsequent treatment. Any patient not known to have had a further second subsequent therapy or death was censored at the last known time to have not received second subsequent therapy
| Months | Olaparib (BRCA1/2 +ve) | Placebo (BRCA1/2 +ve) | Olaparib (BRCA1/2 -ve) | Placebo (BRCA1/2 -ve) |
|---|---|---|---|---|
| Efficacy: Time to Second Subsequent Treatment Commencement (TSST) | 13.1 (11.10 to 15.64) | 11.7 (8.61 to 13.60) | 15.4 (11.60 to 23.62) | 12.7 (10.35 to 16.62) |
TDT was assessed as time from randomisation to study treatment discontinuation or death if this occurs before discontinuation of study treatment. Any patient not known to have died at the time of analysis and not known to have discontinued study treatment was censored based on the last recorded date on which the patient was known to be alive
| Months | Olaparib (BRCA1/2 +ve) | Placebo (BRCA1/2 +ve) | Olaparib (BRCA1/2 -ve) | Placebo (BRCA1/2 -ve) |
|---|---|---|---|---|
| Efficacy: Time to Study Treatment Discontinuation (TDT) | 4.5 (3.35 to 5.59) | 3.4 (2.86 to 5.49) | 5.6 (3.42 to 5.78) | 3.1 (2.79 to 3.91) |
Health related quality of life (HRQoL) of Olaparib maintenance retreatment compared to placebo as measured by the Functional Assessment of Cancer Therapy - Ovarian (FACT-O) Trial Outcome Index (TOI) was determined. HRQoL was analysed using the FACT-O tool by mixed model for repeated measures (MMRM) analysis of the change from baseline in TOI score. FACT-O TOI is scored from O to 100 with higher scores denoting better quality of life. The higher the score, the better the HRQoL.
| Change in scores | Olaparib (BRCA1/2 +ve) | Placebo (BRCA1/2 +ve) | Olaparib (BRCA1/2 -ve) | Placebo (BRCA1/2 -ve) |
|---|---|---|---|---|
| Efficacy: Change From Baseline in Health-related Quality of Life (HRQoL) | -1.27 ± 0.55 | 1.67 ± 0.89 | -2.08 ± 0.60 | 0.58 ± 0.90 |
All AEs/serious adverse events (SAEs) reported during the study were recorded.
| Participants | Olaparib (BRCA1/2 +ve) | Placebo (BRCA1/2 +ve) | Olaparib (BRCA1/2 -ve) | Placebo (BRCA1/2 -ve) |
|---|---|---|---|---|
| Any Treatment emergent adverse event (TEAE) | 64 | 33 | 66 | 31 |
| Any TEAE causally related to treatment | 50 | 23 | 53 | 14 |
| Any TEAE of Common Terminology Criteria for Adverse Events (CTCAE) grade 3 or higher | 11 | 2 | 15 | 3 |
| Any TEAE of CTCAE grade 3 or higher, causally related to treatment | 5 | 1 | 5 | 1 |
| Any TEAE with outcome = death | 0 | 0 | 0 | 0 |
| Any TEAE with outcome = death, causally related to treatment | 0 | 0 | 0 | 0 |
| Any treatment-emergent SAE (including events with outcome = death) | 5 | 0 | 11 | 2 |
| Any treatment-emergent SAE (including events with outcome = death), causally related to treatment | 1 | 0 | 3 | 0 |
| Any TEAE leading to discontinuation of study medication | 2 | 0 | 1 | 0 |
| Any TEAE leading to discontinuation of study medication, causally related to treatment | 1 | 0 | 0 | 0 |
| Any TEAE leading to dose modification | 18 | 6 | 28 | 2 |
| Any TEAE leading to dose modification, causally related to treatment | 14 | 5 | 21 | 1 |
All AESIs reported during the study were recorded.
| Participants | Olaparib (BRCA1/2 +ve) | Placebo (BRCA1/2 +ve) | Olaparib (BRCA1/2 -ve) | Placebo (BRCA1/2 -ve) |
|---|---|---|---|---|
| Number of Patients With Adverse Event of Special Interest (AESI). | 1 | 1 | 1 | 0 |
Collected over From Screening (Day -27 to Day 0) up to 12-weekly beyond 30 days after the last dose of study treatment (assessed up to 3.8 years). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Olaparib (BRCA1/2 +ve) | 39/74 (52.7%) | 5/74 (6.8%) | 64/74 (86.5%) |
| Placebo (BRCA1/2 +ve) | 22/38 (57.9%) | 0/38 (0%) | 33/38 (86.8%) |
| Olaparib (BRCA1/2 -ve) | 15/72 (20.8%) | 11/72 (15.3%) | 65/72 (90.3%) |
| Placebo (BRCA1/2 -ve) | 8/36 (22.2%) | 2/36 (5.6%) | 30/36 (83.3%) |
| Event | Olaparib (BRCA1/2 +ve) | Placebo (BRCA1/2 +ve) | Olaparib (BRCA1/2 -ve) | Placebo (BRCA1/2 -ve) |
|---|---|---|---|---|
| Incarcerated herniaGeneral disorders | 0/74 | 0/38 | 0/72 | 1/36 |
| Hepatic haematomaHepatobiliary disorders | 0/74 | 0/38 | 0/72 | 1/36 |
| COVID-19 pneumoniaInfections and infestations | 2/74 | 0/38 | 0/72 | 0/36 |
| AnaemiaBlood and lymphatic system disorders | 1/74 | 0/38 | 1/72 | 0/36 |
| NeutropeniaBlood and lymphatic system disorders | 1/74 | 0/38 | 1/72 | 0/36 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/74 | 0/38 | 1/72 | 0/36 |
| Supraventricular tachycardiaCardiac disorders | 0/74 | 0/38 | 1/72 | 0/36 |
| DiverticulumGastrointestinal disorders | 0/74 | 0/38 | 1/72 | 0/36 |
| Ileal perforationGastrointestinal disorders | 0/74 | 0/38 | 1/72 | 0/36 |
| IleusGastrointestinal disorders | 0/74 | 0/38 | 1/72 | 0/36 |
| Event | Olaparib (BRCA1/2 +ve) | Placebo (BRCA1/2 +ve) | Olaparib (BRCA1/2 -ve) | Placebo (BRCA1/2 -ve) |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 29/74 | 4/38 | 30/72 | 3/36 |
| Abdominal painGastrointestinal disorders | 8/74 | 11/38 | 6/72 | 6/36 |
| AstheniaGeneral disorders | 18/74 | 3/38 | 15/72 | 2/36 |
| AnaemiaBlood and lymphatic system disorders | 13/74 | 2/38 | 15/72 | 1/36 |
| FatigueGeneral disorders | 13/74 | 5/38 | 13/72 | 2/36 |
| DiarrhoeaGastrointestinal disorders | 10/74 | 5/38 | 12/72 | 2/36 |
| ConstipationGastrointestinal disorders | 9/74 | 6/38 | 9/72 | 2/36 |
| NeutropeniaBlood and lymphatic system disorders | 4/74 | 4/38 | 8/72 | 3/36 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/74 | 3/38 | 2/72 | 4/36 |
| VomitingGastrointestinal disorders | 8/74 | 4/38 | 6/72 | 1/36 |
Full analysis set (FAS) consisted of all randomised patients analysed on an intent-to-treat (ITT) basis.
| Age, Continuous(Years) | Olaparib (BRCA1/2 +ve) | Placebo (BRCA +ve) | Olaparib (BRCA1/2 -ve) | Placebo (BRCA 1/2 -ve) | Total |
|---|---|---|---|---|---|
| Mean | 59.2 ± 9.31 | 61.5 ± 9.22 | 64.2 ± 9.64 | 63.3 ± 9.05 | 61.9 ± 9.54 |
| Age, Customized(Participants) | Olaparib (BRCA1/2 +ve) | Placebo (BRCA +ve) | Olaparib (BRCA1/2 -ve) | Placebo (BRCA 1/2 -ve) | Total |
|---|---|---|---|---|---|
| < 50 | 11 | 3 | 4 | 1 | 19 |
| ≥ 50 to < 65 | 40 | 20 | 29 | 19 | 108 |
| ≥ 65 to < 75 | 20 | 12 | 30 | 11 | 73 |
| ≥ 75 | 3 | 3 | 9 | 5 | 20 |
| Sex: Female, Male(Participants) | Olaparib (BRCA1/2 +ve) | Placebo (BRCA +ve) | Olaparib (BRCA1/2 -ve) | Placebo (BRCA 1/2 -ve) | Total |
|---|---|---|---|---|---|
| Female | 74 | 38 | 72 | 36 | 220 |
| Male | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Olaparib (BRCA1/2 +ve) | Placebo (BRCA +ve) | Olaparib (BRCA1/2 -ve) | Placebo (BRCA 1/2 -ve) | Total |
|---|---|---|---|---|---|
| White | 71 | 35 | 66 | 33 | 205 |
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 1 | 0 | 1 |
| Hawaiian Native or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Other | 3 | 3 | 5 | 2 | 13 |
| Missing Data | 0 | 0 | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Jun 2017 to primary completion in Feb 2021, 44 months.
Results were first posted in Apr 2022, 1 year 2 months after primary completion.
Of 33 phase 3 interventional studies under Carcinoma, Ovarian Epithelial, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 110. This study's 44 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Olaparib
Carcinoma, Ovarian Epithelial →